The abstract is read at the publisher; the summary is JClub's.
Dynamic PET with Me4FDG quantifies renal SGLT-mediated glucose handling in vivo, showing SGLT-activity drops from 33 ± 6% to 10 ± 6% after 2 weeks of SGLT2 inhibition in type 2 diabetes patients.
- Why it matters: Static PET cannot reliably reflect renal glucose handling dynamics, leaving a gap for an organ-specific, quantitative, non-invasive readout of SGLT-mediated function to track disease burden and therapy response.
- What they did: The study developed a clinically interpretable dynamic Me4FDG PET metric (SGLT-activity), validated in mice across diabetes, surgical impairment, short-term SGLT2 inhibition, and controls, then translated to patients with type 2 diabetes (n = 17) at baseline and after 2 weeks of SGLT2 inhibition.
- The result: In patients, SGLT2 inhibition increased urinary glucose (3 ± 9 vs 155 ± 7 mmol/L, P < 0.001) and produced a strong inverse correlation between SGLT-activity and urinary glucose (R = -0.74, P < 0.001), outperforming static PET measures.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.